Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Study suggests immediate statins for heart attack patients

31.08.2004


"Other studies have indicated a benefit for heart attack patients in beginning treatment with statins relatively early, so today the standard practice is to prescribe them upon discharge," says R. Scott Wright, M.D., the Mayo Clinic cardiologist who was the study’s lead investigator in North America. "Our new findings suggest they should be given even earlier, as soon as the patient arrives at the hospital."



The PRINCESS Trial (The PRevention of Ischemic EveNts by Early Treatment of CErivaStatin Study) was designed to test whether very early initiation of statin therapy in hospitalized heart attack patients would prevent deaths and additional heart attacks and reduce the need for bypass surgery or angioplasty.

Within 48 hours of hospitalization, 3,605 patients at 260 medical centers in Europe, Israel, Canada and the United States were randomly assigned to receive either cerivastatin, a potent statin agent, or a placebo. Neither patients nor their physicians knew whether they were receiving the statin or the sugar pill initially, but all of the patients were switched to the statin after three months. Because statins had been proven beneficial as a later-term treatment, withholding the cholesterol-lowering medication for a prolonged period would have been unethical. In the midst of the study, however, cerivastatin’s manufacturer withdrew it from the market due to safety concerns, so the researchers were only able to follow the participants for 4.5 months.


The 1,795 patients initially taking the statin were significantly more likely to reach target levels for LDL (bad) cholesterol, and significantly less likely to have another heart attack or to need surgical or catheter-based interventions to improve blood flow to their hearts during the 4.5 months of follow up.

Dr. Wright says the current study confirms Mayo Clinic’s findings from a retrospective study published in 2001, and indicates that the patient benefits observed are not limited to this particular drug (which is no longer on the market), but are a class effect for statins as a whole. "It is highly unlikely that these results would only apply to cerivastatin, because our previous retrospective study that showed similar benefits involved patients taking a variety of statins," Dr. Wright explains. "By the same token, this broad-based study involving hundreds of hospitals shows that the gains from early statin therapy are not unique to academic medical centers like Mayo Clinic, but can be realized everywhere.

"Physicians should begin treatment of heart attack patients with statins as soon as possible upon admission to the hospital," says Dr. Wright. "And patients should see these results as another reason for them to adhere to the statin therapy prescribed by their physicians."

Lee Aase | EurekAlert!
Further information:
http://www.mayo.edu

More articles from Studies and Analyses:

nachricht Multi-year study finds 'hotspots' of ammonia over world's major agricultural areas
17.03.2017 | University of Maryland

nachricht Diabetes Drug May Improve Bone Fat-induced Defects of Fracture Healing
17.03.2017 | Deutsches Institut für Ernährungsforschung Potsdam-Rehbrücke

All articles from Studies and Analyses >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Giant Magnetic Fields in the Universe

Astronomers from Bonn and Tautenburg in Thuringia (Germany) used the 100-m radio telescope at Effelsberg to observe several galaxy clusters. At the edges of these large accumulations of dark matter, stellar systems (galaxies), hot gas, and charged particles, they found magnetic fields that are exceptionally ordered over distances of many million light years. This makes them the most extended magnetic fields in the universe known so far.

The results will be published on March 22 in the journal „Astronomy & Astrophysics“.

Galaxy clusters are the largest gravitationally bound structures in the universe. With a typical extent of about 10 million light years, i.e. 100 times the...

Im Focus: Tracing down linear ubiquitination

Researchers at the Goethe University Frankfurt, together with partners from the University of Tübingen in Germany and Queen Mary University as well as Francis Crick Institute from London (UK) have developed a novel technology to decipher the secret ubiquitin code.

Ubiquitin is a small protein that can be linked to other cellular proteins, thereby controlling and modulating their functions. The attachment occurs in many...

Im Focus: Perovskite edges can be tuned for optoelectronic performance

Layered 2D material improves efficiency for solar cells and LEDs

In the eternal search for next generation high-efficiency solar cells and LEDs, scientists at Los Alamos National Laboratory and their partners are creating...

Im Focus: Polymer-coated silicon nanosheets as alternative to graphene: A perfect team for nanoelectronics

Silicon nanosheets are thin, two-dimensional layers with exceptional optoelectronic properties very similar to those of graphene. Albeit, the nanosheets are less stable. Now researchers at the Technical University of Munich (TUM) have, for the first time ever, produced a composite material combining silicon nanosheets and a polymer that is both UV-resistant and easy to process. This brings the scientists a significant step closer to industrial applications like flexible displays and photosensors.

Silicon nanosheets are thin, two-dimensional layers with exceptional optoelectronic properties very similar to those of graphene. Albeit, the nanosheets are...

Im Focus: Researchers Imitate Molecular Crowding in Cells

Enzymes behave differently in a test tube compared with the molecular scrum of a living cell. Chemists from the University of Basel have now been able to simulate these confined natural conditions in artificial vesicles for the first time. As reported in the academic journal Small, the results are offering better insight into the development of nanoreactors and artificial organelles.

Enzymes behave differently in a test tube compared with the molecular scrum of a living cell. Chemists from the University of Basel have now been able to...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

International Land Use Symposium ILUS 2017: Call for Abstracts and Registration open

20.03.2017 | Event News

CONNECT 2017: International congress on connective tissue

14.03.2017 | Event News

ICTM Conference: Turbine Construction between Big Data and Additive Manufacturing

07.03.2017 | Event News

 
Latest News

Argon is not the 'dope' for metallic hydrogen

24.03.2017 | Materials Sciences

Astronomers find unexpected, dust-obscured star formation in distant galaxy

24.03.2017 | Physics and Astronomy

Gravitational wave kicks monster black hole out of galactic core

24.03.2017 | Physics and Astronomy

VideoLinks
B2B-VideoLinks
More VideoLinks >>>